Athena Athena

X
[{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Biotheus","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"Approved","date":"January 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Lifeline Ventures","pharmaFlowCategory":"D","amount":"$6.9 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of TILT-123 in Combination with Keytruda for Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics Announces Positive Update on its Phase 1 Immunotherapy Clinical Trials in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Finland\u2019s Lifeline Ventures","pharmaFlowCategory":"D","amount":"$23.8 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TILT Biotherapeutics Announces First Patient Dosed in Phase I Solid Tumors Trial Assessing Oncolytic Adenovirus TILT-123 in Combination with Checkpoint Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"TILT Biotherapeutics","sponsor":"U.S. Department of Defense","pharmaFlowCategory":"D","amount":"$2.0 million","upfrontCash":"Undisclosed","newsHeadline":"TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by TILT Biotherapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The funding aims to support the clinical development of TILT-123 (igrelimogene litadenorepvec) in combination with pembrolizumab for the treatment platinum-resistant/refractory ovarian cancer patients.

            Lead Product(s): Igrelimogene Litadenorepvec,Pembrolizumab

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: U.S. Department of Defense

            Deal Size: $2.0 million Upfront Cash: Undisclosed

            Deal Type: Funding February 14, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TILT-123 (igrelimogene litadenorepvec) is a 5/3 chimeric serotype adenovirus armed with two human cytokines, which is being evaluated in combination with avelumab for squamous cell carcinoma of head and neck, and melanoma.

            Lead Product(s): Igrelimogene Litadenorepvec,Avelumab

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will be used to advance to Phase II the company’s combination trials of TILT-123 which use oncolytic immunotherapies synergistically with checkpoint inhibitors.

            Lead Product(s): TILT-123,Avelumab

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Finland’s Lifeline Ventures

            Deal Size: $23.8 million Upfront Cash: Undisclosed

            Deal Type: Financing February 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TILT-123 is a human 5/3 chimeric adenovirus that has been engineered for targeting, safety and potency, is an oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), designed to stimulate T cells to better fight cancer.

            Lead Product(s): TILT-123

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: Phase I Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 31, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.

            Lead Product(s): TILT-123,Pembrolizumab

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            TILT Biotherapeutics has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.

            Lead Product(s): TILT-123

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 05, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The trial’s objective is to evaluate the safety and efficacy of TILT-123 in combination with pembrolizumab and is designed to also deliver insights about the mechanism of action of TILT-123 in humans.

            Lead Product(s): TILT-123,Pembrolizumab

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: IND Enabling Product Type: Large molecule

            Recipient: Merck & Co

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 14, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Funds will be used to advance TILT's proprietary, best-in-class cytokine armed oncolytic adenovirus, TILT-123, into Phase 1 clinical trials in Europe and the United States, and to prepare for Phase 2 trials.

            Lead Product(s): TILT-123,Tumor infiltrating lymphocytes

            Therapeutic Area: Oncology Product Name: TILT-123

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Lifeline Ventures

            Deal Size: $6.9 million Upfront Cash: Undisclosed

            Deal Type: Financing June 16, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement TILT has granted Biotheus rights for development and commercialization of TILT’s proprietary oncolytic virus TILT-123 in Greater China.

            Lead Product(s): TILT-123

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Biotheus

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY